TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05967689: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Sponsor: Taiho Oncology, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT05967689 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05967689 Rescue Dossier →